Measurable Residual Disease in AML

Jacqueline Cloos; Michael Heuser

Measurable Residual Disease in AML

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	S116-S118
Journal	Clinical Lymphoma Myeloma and Leukemia
Volume	21
Publication status	Published - Sept 2021

Keywords

AML
early relapse detection
leukemia monitoring
methods of residual disease detection
prognostic factors for AML
surrogate endpoint

Cite this

@article{130ebd766aba4867ab74aac06a04a109,

title = "Measurable Residual Disease in AML",

keywords = "AML, early relapse detection, leukemia monitoring, methods of residual disease detection, prognostic factors for AML, surrogate endpoint",

author = "Jacqueline Cloos and Michael Heuser",

year = "2021",

month = sep,

language = "English",

volume = "21",

pages = "S116--S118",

journal = "Clinical Lymphoma Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Measurable Residual Disease in AML

AU - Cloos, Jacqueline

AU - Heuser, Michael

PY - 2021/9

Y1 - 2021/9

KW - AML

KW - early relapse detection

KW - leukemia monitoring

KW - methods of residual disease detection

KW - prognostic factors for AML

KW - surrogate endpoint

M3 - Meeting Abstract

SN - 2152-2650

VL - 21

SP - S116-S118

JO - Clinical Lymphoma Myeloma and Leukemia

JF - Clinical Lymphoma Myeloma and Leukemia

ER -